Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak

2015; American Academy of Pediatrics; Volume: 135; Issue: 5 Linguagem: Inglês

10.1542/peds.2014-4015

ISSN

1098-4275

Autores

Lucy A. McNamara, Alice M. Shumate, Peter Johnsen, Jessica R. MacNeil, Manisha Patel, Tina Bhavsar, Amanda Cohn, Jill Dinitz-Sklar, Jonathan Duffy, Janet Finnie, Denise Garon, Robert Hary, Fang Hu, Hajime Kamiya, Hye-Joo Kim, John Kolligian, Janet Neglia, Judith E. Oakley, J. Wagner, Kathy Wagner, Xin Wang, YU Yon, Barbara Montana, Christina Tan, R. Izzo, Thomas A. Clark,

Tópico(s)

Vaccine Coverage and Hesitancy

Resumo

In 2013-2014, an outbreak of serogroup B meningococcal disease occurred among persons linked to a New Jersey university (University A). In the absence of a licensed serogroup B meningococcal (MenB) vaccine in the United States, the Food and Drug Administration authorized use of an investigational MenB vaccine to control the outbreak. An investigation of the outbreak and response was undertaken to determine the population at risk and assess vaccination coverage.

Referência(s)